171 related articles for article (PubMed ID: 10326705)
21. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
22. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
23. Measurement of cell kinetic parameters in meningiomas.
Nakagawa Y; Sugawa N; Ueda S; Suzuki K; Vignutelli A; Perentes E
Neurol Med Chir (Tokyo); 1997 Jan; 37(1):12-7. PubMed ID: 9046799
[TBL] [Abstract][Full Text] [Related]
24. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].
Miyagami M; Nakamura S
No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195
[TBL] [Abstract][Full Text] [Related]
25. Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB 1 antibody in formalin-fixed paraffin sections.
Skalova A; Leivo I; Von Boguslawsky K; Saksela E
J Pathol; 1994 May; 173(1):13-21. PubMed ID: 7931834
[TBL] [Abstract][Full Text] [Related]
26. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
Devaprasath A; Chacko G
Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
[TBL] [Abstract][Full Text] [Related]
28. Proliferation index determined by MIB-1 and recurrence in endometrial cancer.
Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
Gynecol Oncol; 1996 Jun; 61(3):373-7. PubMed ID: 8641618
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
[TBL] [Abstract][Full Text] [Related]
30. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
[TBL] [Abstract][Full Text] [Related]
31. Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors.
Asano K; Takeda T; Nakano T; Ohkuma H
Brain Tumor Pathol; 2010 Apr; 27(1):1-6. PubMed ID: 20425041
[TBL] [Abstract][Full Text] [Related]
32. The impact of progesterone receptor expression on relapse in the long-term clinical course of 93 benign meningiomas.
Strik HM; Strobelt I; Pietsch-Breitfeld B; Iglesias-Rozas JR; Will B; Meyermann R
In Vivo; 2002; 16(4):265-70. PubMed ID: 12224136
[TBL] [Abstract][Full Text] [Related]
33. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas.
Torp SH; Lindboe CF; Granli US; Moen TM; Nordtømme T
Clin Neuropathol; 2001; 20(5):190-5. PubMed ID: 11594503
[TBL] [Abstract][Full Text] [Related]
34. Primary resected meningiomas: relapses and proliferation markers.
Kalala JP; Caemaert J; De Ridder L
In Vivo; 2004; 18(4):411-6. PubMed ID: 15369177
[TBL] [Abstract][Full Text] [Related]
35. [Craniopharyngioma with rapid regrowth--role of MIB-1 labeling index].
Anegawa S; Hayashi T; Nakagawa S; Furukawa Y; Tomokiyo M
No Shinkei Geka; 2001 Aug; 29(8):727-33. PubMed ID: 11554090
[TBL] [Abstract][Full Text] [Related]
36. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods.
Nakasu S; Li DH; Okabe H; Nakajima M; Matsuda M
Am J Surg Pathol; 2001 Apr; 25(4):472-8. PubMed ID: 11257621
[TBL] [Abstract][Full Text] [Related]
37. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
38. Tumor doubling time as preoperative predictor of malignancy and recurrence in newly diagnosed meningioma.
Miwa Y; Sugawara T; Kobayashi D; Maehara T
Neurosurg Rev; 2022 Dec; 45(6):3683-3687. PubMed ID: 36136254
[TBL] [Abstract][Full Text] [Related]
39. Recurrence and regrowth of benign meningiomas.
Nakasu S; Fukami T; Jito J; Nozaki K
Brain Tumor Pathol; 2009; 26(2):69-72. PubMed ID: 19856217
[TBL] [Abstract][Full Text] [Related]
40. The role of MIB-1 index in the prognosis of resectable pancreatic head cancer.
Shyr YM; Su CH; Li AF; Wu CW; Lui WY
Hepatogastroenterology; 1999; 46(29):2968-73. PubMed ID: 10576384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
